Category Archives: Current in Entrepreneurship

When Will the COVID-19 Pandemic End?

This article updates McKinsey & Co. perspectives on when the coronavirus pandemic will end to reflect the latest information on vaccine rollout, variants of concern, and disease progression. 

March 26, 2021

The fall in COVID-19 cases across much of the world over the past ten weeks signals a new dawn in the fight against the disease. Vaccines are proving effective and rapidly scaling, bending the curve in many geographies. This is a fragile dawn, however, with transmission and deaths still high, unequal access to vaccines, and variants of concern threatening to undo progress to date

The trajectory of UK and US cases has enabled the beginnings of a transition toward normalcy,1 the first and more important of the pandemic’s two endpoints. We expect this transition to continue in the second quarter of 2021 and will likely see many aspects of social and economic life return to the prepandemic normal, consistent with UK Prime Minister Johnson’s staged reopening plan for the United Kingdom2 and US President Biden’s goal of a normal Independence Day.3 We are more confident in this timeline for the United Kingdom than for the United States, given that the first has already experienced a wave driven by a more infectious variant, whereas the latter could still face one. Parts of the European Union have recently faced setbacks: fewer doses in arms than in the United Kingdom or United States, a new wave of cases, and new lockdowns. A transition toward normalcy is mostly likely in Europe during the late second or third quarter of 2021. The timing will probably vary by country, depending on accelerating vaccine supplies, the impact of vaccinations on hospitalization rates, and the occurrence (or not) of new waves driven by new variants.

Herd immunity, the second endpoint, is most likely in the third quarter for the United Kingdom and the United States and in the fourth quarter for the European Union, with the difference driven by a more limited vaccine availability in the European Union. However, the risks to these timelines are real—herd immunity may not be achieved by the end of the year if vaccine hesitancy is high, if countries experience disruptions in vaccine supply, or if a variant that renders existing vaccines less effective spreads widely. And herd immunity may look different in different parts of the world, ranging from strong nationwide or regional protection to temporary or oscillating immunity to some countries not reaching herd immunity over the medium term.

In this article, we’ll review the developments since our last perspective (January 21), offer an outlook for each of the three geographies, assess risks, and outline what the end of the pandemic might look like.

Recent developments and their impact on timelines

The past month or two have seen seven important developments:

  1. Vaccines work. We have growing evidence that vaccines are effective, as real-world data from Israel and the United Kingdom validate the clinical-trial results by showing a sharp reduction in hospitalizations and deaths.4 Emerging evidence also indicates that vaccines likely reduce transmission considerably, though not to the same degree that they prevent severe disease.5
  2. The vaccine rollout is improving. Massive inoculation programs have accelerated, especially in the United Kingdom. As of March 15, the United Kingdom has administered 39 doses per 100 people in the total population; the corresponding figures for the United States and the European Union are 33 and 12 per 100, respectively.6 Just as important: sentiment about vaccine adoption is improving.7
  3. More vaccines are coming. Johnson & Johnson’s one-shot vaccine appears to be highly effective against severe COVID-19 and received Emergency Use Authorization in the United States on February 27.8 Novavax’s vaccine is now in Phase III trials; preliminary results suggest it was highly effective in the United Kingdom but less so in South Africa.9 All of that makes it increasingly clear that the United Kingdom and the United States will have enough doses to vaccinate all adults by the end of the second quarter, and Europe should achieve the same milestone by the end of the third quarter, assuming no major vaccines are withdrawn. Further, vaccine trials on children aged 12 and up are well underway, and new trials on babies and children six months and older raise the possibility of pediatric vaccination, which would add to the population that could potentially contribute to herd immunity.10
  4. Therapeutics are poised to make more of a difference. A new wave of COVID-19 therapeutics, including those from Eli Lilly,11 Merck–Ridgeback,12 and Vir Biotechnology,13 have produced positive data or received Emergency Use Authorization. The emerging data from these treatments suggest they have the potential to materially reduce hospitalizations and deaths for cases that do occur, accelerating a transition toward normalcy.
  5. New cases and deaths are lower—but still high. New cases, hospitalizations, and deaths have dropped dramatically—by 79 percent and 89 percent, respectively, in the United States and the United Kingdom from the January peak, as of March 15.14 This trajectory has amplified discussions of a transition toward normalcy in both countries. The bend in the curve is fragile, however. Much of the decline in Europe has followed strict lockdowns; but lockdowns and other nonpharmaceutical interventions are still confoundingly difficult to get right, and even now, multiple European countries are experiencing upward case trends. And US deaths are still averaging 1,000 per day, many times higher than average daily flu deaths.15
  6. It is increasingly clear that more infectious variants of concern16 may drive a new wave of cases in the coming months. The United Kingdom is in a relatively favorable position; cases are declining in spite of the high prevalence of the B.1.1.7 variant, suggesting that the country has a demonstrable ability to control the spread of more infectious variants. In contrast, the United States and parts of the European Union appear to have an increasing prevalence of B. The potential for a variant-driven wave of US cases and ongoing spread in Europe in the coming months is real.
  7. Variants may also reduce vaccine efficacy or enable reinfection. Data from the AstraZeneca vaccine trial in South Africa highlight the potential for variants such as B.1.351 and P.1 to reduce the efficacy of vaccines.18 Other vaccine data, including those from Novavax and Johnson & Johnson, show a more modest reduction in efficacy, especially against severe disease caused by these variants.19 There is also early evidence of mutations arising independently in the United States that may reduce the efficacy of vaccines.20 These variants also appear to be more infectious than the original wild-type strain. These initial findings are based on very small sample sizes and may change as more information becomes available; we still do not know the impact of vaccines against severe disease from these strains. But if these results hold up, the spread of strains against which existing vaccines are substantially less effective would be a significant risk to lives and could delay the end of the pandemic.

What’s the net impact of all these developments? The data continue to indicate, as stated in our earlier perspectives, that a significant transition toward UK and US normalcy will occur in the second quarter of 2021, although the potential for a variant-driven wave in the United States is real and would blunt the transition (Exhibit 1). Potential herd-immunity timelines are bifurcating as a result of growth in variants that may reduce vaccine efficacy. If the variants turn out to be a minor factor (they only reduce vaccine efficacy modestly, or they don’t spread widely), then herd immunity in the second half of the year is likely for both countries—and is more likely in the third quarter than the fourth. However, if the impact of these variants is significant, we could see timelines significantly prolonging into late 2021 or beyond.

How does this vary by geography? Most of our analysis in this series has focused on the United Kingdom and the United States, which continue to move down a similar path. The end of Europe’s pandemic may come somewhat later, and other countries’ outlooks will depend on several variables.

European Union. Here, as in other regions, the timing of access to vaccines will be the biggest driver of the end of the pandemic. Levels of natural immunity from prior infection vary within the European Union but are generally in the same range as in the United Kingdom and the United States.21 Seasonality is likely to work in similar ways. And public interest in vaccination appears to be similar too, even in countries such as France, where interest in vaccination was significantly lower than in other countries in the region but may now be improving.22 The prevalence of the more infectious B.1.1.7 variant varies by country; most countries with cases are between the high UK levels and lower US levels.

Exhibit 2 lays out the likely timing of vaccine availability in the European Union. Broadly speaking, availability will be similar to that of the United Kingdom and the United States, but EU countries may need to wait a few months longer to vaccinate all adults. Please note that this would be subject to change and further delay if the Oxford–AstraZeneca vaccine remains suspended in multiple countries following concerns about blood clots; WHO has confirmed its continued support of the vaccine.23

Given that sufficient vaccine doses are available to vaccinate the highest-risk populations in the coming months, we expect to see the EU transition to normalcy during the second quarter of the year, although the start of this transition may be delayed until late in the quarter by a new wave of cases in some countries. A key difference for the European Union, as compared with the United Kingdom and the United States: herd immunity is more likely in the fourth quarter than the third quarter, given the likely timeline of vaccine delivery (Exhibit 3).While the European Union, the United Kingdom, and the United States have had broadly similar COVID-19 experiences, other parts of the world look very different. Countries like New Zealand have avoided significant COVID-19-associated mortality but appear to be further from herd immunity because so few New Zealanders have infection-driven immunity to SARS-CoV-2. On the other hand, if vaccine uptake is fast, New Zealand might achieve a longer-lasting vaccine-based herd immunity. A second factor is seasonality: the timing of seasonality-driven changes will be different in tropical locations and the Southern Hemisphere. A third is demographics: while the younger populations of many lower-income countries have led to lower COVID-19-associated mortality, they also make it harder for adult-only vaccination programs to drive herd immunity. And perhaps most importantly for timelines, access to vaccines is unequal. While COVAX and other access initiatives are working to close the gap, many low-income countries may not receive enough doses to vaccinate all adults until well into 2022. The world is on pace to manufacture enough —or close to 100 percent of the adult population—by the end of 2021, but the distribution of these doses may continue to be asymmetric.

Rest of the world. While the European Union, the United Kingdom, and the United States have had broadly similar COVID-19 experiences, other parts of the world look very different. Countries like New Zealand have avoided significant COVID-19-associated mortality but appear to be further from herd immunity because so few New Zealanders have infection-driven immunity to SARS-CoV-2. On the other hand, if vaccine uptake is fast, New Zealand might achieve a longer-lasting vaccine-based herd immunity. A second factor is seasonality: the timing of seasonality-driven changes will be different in tropical locations and the Southern Hemisphere. A third is demographics: while the younger populations of many lower-income countries have led to lower COVID-19-associated mortality, they also make it harder for adult-only vaccination programs to drive herd immunity. And perhaps most importantly for timelines, access to vaccines is unequal. While COVAX and other access initiatives are working to close the gap, many low-income countries may not receive enough doses to vaccinate all adults until well into 2022.24 The world is on pace to manufacture enough doses for 80 percent of the global population—or close to 100 percent of the adult population—by the end of 2021, but the distribution of these doses may continue to be asymmetric.

Exhibit 4 provides a global view of seven factors that are likely to drive herd-immunity timelines for the rest of the world. These factors include the following:

  • Population vaccinated—the proportion of people who have received the vaccine so far
  • Vaccine courses secured—the additional supplies for which a country has contracted
  • Supply-chain readiness
  • Consumer vaccine sentiment—the public’s willingness to be vaccinated
  • Population under 19 years of age—a greater proportion of children makes a transition toward normalcy easier to achieve but herd immunity more difficult
  • Natural immunity, or the rate of prior COVID-19 infection—higher historical infection rates decrease the vaccination rate needed to achieve herd immunity
  • Prevalence of variants of concern

Risks to herd immunity

Herd immunity requires that enough people be simultaneously immune to SARS-CoV-2 to prevent widespread ongoing transmission. While data indicate that the most likely scenario is to reach this state on the timelines described above, five risks could delay progress.

First, vaccine adoption may prove lower than expected. That could happen if a real or perceived safety issue increases hesitancy or if younger populations see little reason to be vaccinated once older cohorts are protected and a transition toward normalcy is well underway. Second, herd immunity relies on the efficacy of vaccines at reducing transmission (rather than the usually reported efficacy at preventing disease in the vaccinated person). While initial data suggest that COVID-19 vaccines do block significant transmission,25 the efficacy rate may not prove high enough to drive herd immunity. Third, the duration of vaccine-mediated immunity may prove shorter than anticipated, making it hard to reach the necessary threshold for simultaneous immunity. Fourth, supply-chain disruptions and delays are real, and could produce supply shocks and interfere with timelines. Fifth, and most concerning, variants that reduce the efficacy of vaccines or the benefits of natural immunity may spread widely. Some initial data offer concerning evidence that B.1.351 and P.1 may be examples of such variants, although recent Novavax data (with a small sample size) offer some reassurance that its vaccine is effective against severe disease caused by B1.351.26 Similarly, limited data from the Pfizer-BioNTech and AstraZeneca vaccines show evidence of some protection against P.1.27    

These five factors combined mean that there is still a meaningful chance that herd immunity is not reached in the medium term.

From theory to practice: What the ‘end’ might look like

The pandemic’s two endpoints, a transition toward normalcy and herd immunity, may look different in different places. As the name implies, a transition will include a series of steps that will gradually normalize aspects of social and economic life. The order and pace of these steps will vary by geography. Not everyone will immediately resume all of their prepandemic activities; rather, there will be a noticeable shift toward more of them. Steps may include a return to fully in-classroom education, fewer restrictions on the operations of bars and restaurants, more gatherings with larger groups of people, the reopening of offices, and fewer prohibitions on interregional or international travel. The United Kingdom’s plan for reopening provides an example of the stepwise manner in which a transition to normalcy is likely to occur.28

Herd immunity will represent a more definitive end to the pandemic. Isolated cases may still occur—indeed, the virus may continue to circulate for one or more quarters after herd immunity is reached. But with herd immunity, population-wide public-health measures can be phased out. As populations get closer to this state, it may be helpful to introduce some nuance to what we mean by the term.

  1. Nationwide herd immunity. The full population is well protected so that the country experiences, at most, occasional small flare-ups of disease. This scenario is most likely in smaller countries where immunity to COVID-19 can become uniformly high.
  2. Regional herd immunity. Some regions, states, or cities are well protected, while others experience ongoing outbreaks of COVID-19. In large, diverse countries like the United States, this situation is especially easy to imagine.
  3. Temporary herd immunity. A population or region achieves herd immunity for some period, but as variants are introduced, against which prior immunity is less effective, a new wave of cases is launched. Another potential trigger for such a wave could come as immunity (particularly natural immunity) wanes. As the number of new cases of COVID-19 falls globally, the rate of emergence of important variants should also decrease, but some risk will remain.
  4. Endemicity. A region fails to achieve herd immunity. Endemicity is most likely in places where vaccine access is limited, where few people choose to be vaccinated, if the duration of immunity is short, or variants that reduce vaccine efficacy are common and widespread. Endemicity might include cyclic, seasonal waves of disease, broadly similar to the flu, or a multiyear cycle of resurgence.

The next few years are likely to see a combination of some or all of these options around the world. Given the likely timing of herd immunity in various geographies and the uncertain duration of protection from vaccines (both duration of immune response and efficacy versus new variants), it is likely that some measures such as booster vaccines are likely to be required indefinitely. Herd immunity is not the same as eradication. SARS-CoV-2 will continue to exist. Even when a country reaches herd immunity, ongoing surveillance, booster vaccines, and potentially other measures may be needed.

Courtesy McKinsey & Co. Insights


Slope of the Curve, by Working Nation

Those who read this blog regularly know Clint Day has preached the danger of the “Perfect Storm” shown  below. No one has better depicted the impact of the Perfect Storm on the U. S. workforce than the video by Working Nation also shown below.  The most prominent solution is teaching, facilitating, and helping spread the skill of…entrepreneurship.  Thanks to the internet and Silicon Valley’s invention of its lean startup entrepreneurship it  can be taught and, more importantly, learned by anyone with desire.  The reason is evidenced-based planning where an end-user, the persona with a problem or a need, helps design the product through Steve Blank’s customer development process. Now displaced truck drivers, for example, can use a hobby, interest or past work experience to start their own small, successful business.

Start with learning an entrepreneurial mindset by reading Kyle Garman’s book The Entrepreneurial Mindset and watch  Next choose an idea you are passionate about that fills a need.  Try to have an emotional investment in the concept and read this article /howtofindyourpassion.html. Finally, learn lean startup from and video as you find a mentor at a college entrepreneurship program, an incubator or the state SBDC (Small Business Development Center).

The Slope of the Curve (by Working Nation) 

Only Entrepreneurs Will Survive in a World That Only Gets Faster

One of the bright minds in our entrepreneurship field is MIT Sloan Professor of the Practice Bill Aulet. Author of Discipline Entrepreneurship used to build startups globally.  Here is an interview by Robert Thurston last month for the SFMBA Roundtable 5-Star rated.

If the pace, abruptness, and unpredictability of change during the global pandemic has you hoping for a chance to catch your breath, MIT Sloan Professor of the Practice Bill Aulet has a word of caution. “The world never will be slower than it is today,” he says. “That’s a fundamental state of affairs that entrepreneurs must embrace if they are to thrive in the midst of—and most certainly beyond—this current global crisis.”

“The traditional approach to launching an enterprise is based on a command/control/conquer model,” says Aulet. “Gain control of resources and overpower your competitors. Go forth and win. The problem is that this approach only serves to optimize large organizations into doing what they’ve always done—which builds in a perilous fragility that can cripple a company when the marketplace and the world become more fluid and chaotic.”

According to Aulet, many leaders default to a posture of being robust and resilient in the midst of a crisis. “Robustness is a trap, however, because it’s actually a neutral condition,” he warns. “Robust people and teams maintain their course when faced with adversity or unexpected events. In today’s world, weathering storms by continuing to march straight ahead is not a sufficient condition for success.”

Building ventures that don’t break

The Martin Trust Center, by contrast, teaches what it refers to as a resilience-plus approach. “Resilience-plus comprises a mindset, a skillset, and a mode of operation better suited to chaotic, rapidly evolving circumstances,” says Aulet. “We want our students to embrace adversity as an invitation to up their games in the same way that champion athletes or great artists transform setbacks into greater creativity and higher levels of performance. That’s the resilience-plus mindset.”

Aulet summarizes the skillset in six points.
• Understand how technology trends are changing and look ahead to what’s next.
• Track changing consumer behavior patterns and the evolution of cultural norms.
• Build an organizational strategy that capitalizes on your understanding of what lies in the future.
• Be prepared to step on the gas when you see a new opportunity emerging in the marketplace.
• Continually iterate to create a spiral of innovation that refines your response to new opportunities.
• Run data-driven experiments to test and perfect your operating assumptions about future trends.

“Companies that excel in these areas—Zoom, Peloton, Netflix, Grubhub, for example—have thrived during the pandemic,” notes Aulet. “They each invested heavily in their assumptions about changing consumer behavior before COVID. When the crisis presented a window of opportunity, each company accelerated and evolved their offerings to meet the moment.”

A Marshall Plan for entrepreneurship in the U.S.

Going forward, Aulet sees an even greater need for MIT-style entrepreneurship across the country. “Forget any notion of restoring what existed pre-pandemic,” he advises. “We will have more health crises, additional civil unrest, greater climate-driven challenges, additional economic disruption. To succeed under those circumstances, companies must resist the natural temptation to hunker down and focus just on what they themselves do well. For the resilience-plus entrepreneur, the flipside of less control is greater opportunity to collaborate.”

Aulet believes a community approach will drive the next wave of entrepreneurship in the U.S. “Don’t let a lack of control over resources discourage you from pursuing a new opportunity that you believe is right for your company,” he says. “Instead, tap into the skills and resources that lie within your network but outside your organization. If you can create something of value through collaboration, you can help build an ecosystem in which every party gains something for their investment in a particular project. Be a great collaborator, and you will attract great collaborators.”

Even though the Martin Trust Center approach has gained global recognition, Aulet believes there’s much more work to be done. “If the world is coming around to us,” he says, “then we need to reach further out into the world. Kentucky, Ohio, Idaho, Pennsylvania, you name it. The entrepreneurial spirit is out there, waiting to be tapped in places where people feel alienated and believe they have little control over their destinies. My hope for the future is that young entrepreneurs will not only be inspired to make money but to make more entrepreneurs. If we build more resilience-plus people, we will build a resilience-plus society.”

Calm down: Your work and life may depend on it

Continual, or chronic, stress can cause mood swings, reduced empathy, and impulse-control issues. It’s also associated with an increased risk of cardiovascular disease and stroke.  Stress and anxiety are common experiences for most people. In fact, 70% of adults in the United States say they feel stress or anxiety daily.  How to relieve it:

  1. Exercise. Exercise is one of the most important things you can do to combat stress. …
  2. Consider supplements. Several supplements promote stress and anxiety reduction. …
  3. Light a candle. …
  4. Reduce your caffeine intake. …
  5. Write it down. …
  6. Chew gum. …
  7. Spend time with friends and family. …
  8. Laugh
  9. Exercise
  10. Take a yoga class